DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for Middle East respiratory syndrome — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMiddle East respiratory syndrome maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for middle east respiratory syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cytochrome P450 family 3 subfamily A member 4 (CYP3A4) — CYP3A4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5VCC · 1.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
Since MERS was first reported in 2012, the case fatality rate has been approximately 36%. In the United States between January 2013 and October 2014, only two imported cases were detected among 490 patients under investigation. Continued awareness is needed for early case detection and implementation of infection control measures.
In a 2021 study using common marmosets as an animal model, infection by aerosol, intranasal, and oral routes resulted in no or mild disease, and all animals mounted an immunological response. The work demonstrated that higher concentrations of virus are required to cause overt disease, and that an appropriate early immunological response is able to control the infection. This suggests the animal model may not reliably reproduce severe human disease.
A 2015 review of MERS in children noted severe clinical symptoms and high mortality as concerns, but did not report any specific paediatric case numbers, treatment outcomes, or drug efficacy data from clinical trials. No drug is mentioned in any of the abstracts as having been tested against MERS in humans or animals.
What is still missing is a reproducible animal model that mirrors the 36% human case fatality rate, any randomised controlled trial of a therapeutic agent in patients, and a clear stratification of which patient groups (such as children or the immunocompromised) might benefit from early intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Evaluation of Patients under Investigation for MERS-CoV Infection, United States, January 2013–October 2014
AbstractMiddle East respiratory syndrome (MERS) cases continue to be reported from the Middle East. Evaluation and testing of patients under investigation (PUIs) for MERS are recommended. In 2013-2014, two imported cases were detected among 490 US PUIs. Continued awareness is needed for early case detection and implementation of infection control measures.
Journal of Virology · 2021 · 3 citations · open access
Comparison of Experimental Middle East Respiratory Syndrome Coronavirus Infection Acquired by Three Individual Routes of Infection in the Common Marmoset
AbstractMiddle East respiratory syndrome is caused by a human coronavirus, MERS-CoV, similar to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Humans typically exhibit fever, cough, shortness of breath, gastrointestinal issues, and breathing difficulties, which can lead to pneumonia and/or renal complications. This emerging disease resulted in the first human lethal cases in 2012 and has a case fatality rate of approximately 36%. Consequently, there is a need for medical countermeasures and appropriate animal models for their assessment. This work has demonstrated the requirement for higher concentrations of virus to cause overt disease. Challenge by the aerosol, intranasal, and oral routes resulted in no or mild disease, but all animals had an immunological response. This shows that an appropriate early immunological response is able to control the disease.
Current status of Middle East respiratory syndrome in children
AbstractSince Middle East respiratory syndrome (MERS) was first reported in 2012, the severe clinical symptoms and high mortality have been concerned.The epidemiology, possible pathogenesis, clinical manifestations (especially in children), treatment and counter measures of MERS were reviewed in this paper.
Key words:
Middle East respiratory syndrome; Coronavirus; Child; Treatment; Prevention
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
